- Home
- CYCC vs FBIO Comparison
CYCC vs FBIO Comparison
Compare CYCC & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- FBIO
- Stock Information
- Founded
- CYCC 1992
- FBIO 2006
- Country
- CYCC Malaysia
- FBIO United States
- Employees
- CYCC N/A
- FBIO N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CYCC Health Care
- FBIO Health Care
- Exchange
- CYCC Nasdaq
- FBIO Nasdaq
- Market Cap
- CYCC 61.2M
- FBIO 49.1M
- IPO Year
- CYCC N/A
- FBIO N/A
- Fundamental
- Price
- CYCC $1.63
- FBIO $1.89
- Analyst Decision
- CYCC
- FBIO Strong Buy
- Analyst Count
- CYCC 0
- FBIO 3
- Target Price
- CYCC N/A
- FBIO $21.00
- AVG Volume (30 Days)
- CYCC 191.0K
- FBIO 178.7K
- Earning Date
- CYCC 05-15-2025
- FBIO 05-15-2025
- Dividend Yield
- CYCC 147.24%
- FBIO N/A
- EPS Growth
- CYCC N/A
- FBIO N/A
- EPS
- CYCC N/A
- FBIO N/A
- Revenue
- CYCC $14,000.00
- FBIO $57,784,000.00
- Revenue This Year
- CYCC $137.21
- FBIO $63.20
- Revenue Next Year
- CYCC N/A
- FBIO $66.70
- P/E Ratio
- CYCC N/A
- FBIO N/A
- Revenue Growth
- CYCC N/A
- FBIO N/A
- 52 Week Low
- CYCC $1.36
- FBIO $1.33
- 52 Week High
- CYCC $49.34
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- CYCC 32.89
- FBIO 60.90
- Support Level
- CYCC $1.36
- FBIO $1.66
- Resistance Level
- CYCC $1.94
- FBIO $1.96
- Average True Range (ATR)
- CYCC 0.43
- FBIO 0.11
- MACD
- CYCC -0.07
- FBIO 0.02
- Stochastic Oscillator
- CYCC 8.31
- FBIO 80.56
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.